The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...

Commentary: Americans generally pay more for brand-name drugs, but also pay significantly less for most generics: over 90% of ...

In what some news reports dubbed " an awkward moment ," CMS Administrator Mehmet Oz, MD, stepped up to the podium in the Oval Office last week to correct President Donald Trump on the status of GLP-1 ...

In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...

WeightWatchers said on Monday it will partner with Amazon to deliver medications including injectable GLP-1 obesity ...

WW International shares rise nearly 6% after announcing a partnership with Amazon Pharmacy to deliver GLP-1 weight-loss drugs directly to customers.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

President Trump wants to lower GLP-1 prices; Novo Nordisk hires new corporate affairs lead; FDA announces priority drug review candidates.

President Donald Trump on Friday announced a deal with pharmaceutical company Merck and its U.S. subsidiary, EMD Serono, to ...